Cipla Q4FY26 preview: profit seen down 42% YoY

What the Q4FY26 results preview is signalling

Cipla is expected to report a sharp year-on-year decline in profit and margins for the January to March quarter of FY26 (Q4FY26), as key product contributions fade in the US. Brokerages tracked by Business Standard expect the absence of gRevlimid revenue and lower Lanreotide sales to weigh on profitability, even as domestic formulations continue to show healthy traction. Sequentially, analysts also see pressure on both revenue and profit due to an unfavourable product mix and higher operating costs.

The Mumbai-headquartered pharmaceutical company is scheduled to announce Q4FY26 results on Wednesday, May 13, 2026. With multiple moving parts across geographies, investor focus is likely to remain on the US pipeline commentary and early traction from recent GLP launches in India.

Revenue expectations: slight dip YoY, sharper fall QoQ

Consensus expectations point to a marginal decline in consolidated revenue to ₹6,665 crore in Q4FY26, compared with ₹6,730 crore in the year-ago quarter. On a quarter-on-quarter basis, revenue is expected to decline 5.8% from ₹7,074.5 crore in Q3FY26.

The modelling reflects a mixed picture across markets. India is expected to stay resilient, but weakness in the US is likely to dominate the consolidated outcome for the quarter. Analysts have also highlighted seasonality as a factor that can make the March quarter relatively softer.

Profit after tax: brokerages model a steep drop

Cipla’s profit after tax (PAT) is expected at ₹700 crore for Q4FY26 versus ₹1,222 crore in the same quarter last year, implying a 42% year-on-year decline. Sequentially, profit is estimated to fall 21% from ₹884.20 crore reported in Q3FY26.

Brokerage commentary attributes the expected PAT decline largely to the absence of high-margin product contributions and the knock-on effect on operating leverage. Rising costs such as marketing and freight are also expected to add pressure.

Ebitda and margin: product mix hurts profitability

On the operating front, Ebitda is expected to decline nearly 35% year-on-year to ₹1,000 crore in Q4FY26 from ₹1,538 crore a year ago. On a sequential basis, Ebitda may fall 20% from ₹1,255 crore in the December 2025 quarter.

Analysts broadly point to a “high base” in the US market and an unfavourable product mix as the main drivers of margin compression. Minimal contribution from high-value products such as gRevlimid and Lanreotide is expected to hurt margins meaningfully. Costs are also expected to rise due to marketing and advertising linked to GLP launches in March 2026, and higher freight costs tied to the ongoing Middle East conflict.

gRevlimid and Lanreotide: the core swing factors

Kotak Institutional Equities expects a sharp decline in sales as gRevlimid and Lanreotide will have minimal contribution in Q4FY26. It factors in “nil” gRevlimid sales due to patent expiry and expects US sales to decline to $136 million, a 19% sequential drop.

Antique stock broking similarly expects stronger domestic formulations to be offset by a weaker US market. It projects Cipla’s US sales to decline 21% year-on-year to $174 million, largely due to the gRevlimid factor.

The Lanreotide situation has also been in focus. Cipla’s disclosures and commentary cited a temporary pause in Lanreotide supply linked to US FDA inspection observations at a partner’s manufacturing facility, with the disruption expected to impact revenues until supply resumes in H1 FY27.

India business: steady growth expectations provide a cushion

Despite US headwinds, brokerages expect continued momentum in India. Kotak expects 12% growth in domestic sales, aided by the scale-up of Yurpeak. Antique also expects domestic growth of 12%, driven by the respiratory portfolio.

From Q3FY26 commentary, Cipla reported the One India business growing 10% year-on-year, with respiratory growth of 11% year-on-year. This domestic resilience is a recurring theme in Q4FY26 previews, even though consolidated margins are expected to remain under pressure.

Q3FY26 context: what management has already guided

Cipla reported Q3FY26 revenue of ₹7,074 crore, which it said was flat year-on-year, with strong India performance offset by declines in US generic REVLIMID and Lanreotide sales. For that quarter, Ebitda margin (excluding other income) stood at 17.7%, and management attributed the decline primarily to lower generic REVLIMID revenues and higher R&D investment.

Management reiterated an FY26 Ebitda margin target of around 21%, while acknowledging headwinds from REVLIMID’s loss and near-term Lanreotide disruption. Cipla also indicated that US revenue guidance for FY27 will be lowered due to the Lanreotide supply disruption. North America revenue for the quarter was stated at $167 million.

Market impact: what investors will track on May 13

For markets, the key issue is the visibility on US recovery once gRevlimid normalises to a lower base and Lanreotide supply stabilises. Investors are also likely to parse management’s pipeline commentary, given references to planned respiratory and peptide launches over the next 12 months.

In India, attention is expected on the early commercial ramp-up of recent GLP launches and whether marketing costs remain elevated beyond the launch window. Brokerages have also flagged freight cost inflation due to geopolitical disruptions, which can affect near-term profitability if sustained.

Key numbers to watch in the Q4FY26 print

Conclusion

Cipla’s Q4FY26 is expected to reflect a weaker quarter operationally, with brokerages modelling lower revenue, a sharp decline in PAT and softer Ebitda as gRevlimid and Lanreotide contribute minimally. At the same time, domestic formulations are expected to remain supportive, with analysts pointing to growth led by respiratory and the Yurpeak scale-up.

On May 13, the market is likely to focus on management’s update on the US pipeline, the timeline for Lanreotide supply normalisation into H1 FY27, and how costs tied to GLP launches and freight are trending.